About ATP synthase peripheral stalk subunit b, mitochondrial
ATP synthase peripheral stalk subunit b, mitochondrial (ATP5PB) is a protein
from Homo sapiens identified by UniProt accession
P24539, 256 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | ATP synthase peripheral stalk subunit b, mitochondrial |
|---|
| UniProt accession | P24539 |
|---|
| Gene | ATP5PB |
|---|
| Organism | Homo sapiens |
|---|
| Length | 256 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (38)
Diseases linked to this target (Open Targets).
- t-tau:beta-amyloid 1-42 ratio measurement · score 0.02
- ulcerative colitis · score 0.02
- nonpapillary renal cell carcinoma · score 0.01
- Abnormal sperm morphology · score 0.01
- Hyperglycemia · score 0.01
- Alzheimer disease · score 0.01
- diabetic nephropathy · score 0.01
- Acute kidney injury · score 0.01
- hepatocellular carcinoma · score 0.01
- ovarian carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P24539-F1 | alphafold | PREDICTED | 83.28 | — |
Amino-acid sequence (256 residues)
MLSRVVLSAA ATAAPSLKNA AFLGPGVLQA TRTFHTGQPH LVPVPPLPEY GGKVRYGLIP EEFFQFLYPK TGVTGPYVLG TGLILYALSK EIYVISAETF TALSVLGVMV YGIKKYGPFV ADFADKLNEQ KLAQLEEAKQ ASIQHIQNAI DTEKSQQALV QKRHYLFDVQ RNNIAMALEV TYRERLYRVY KEVKNRLDYH ISVQNMMRRK EQEHMINWVE KHVVQSISTQ QEKETIAKCI ADLKLLAKKA QAQPVM
Explore ATP synthase peripheral stalk subunit b, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets